Clovis Oncology to receive $175M to fund company’s largest clinical trial

Clovis Oncology to receive $175M to fund company’s largest clinical trial

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced it has entered into an agreement for up to $175 million in non-dilutive clinical trial financing with certain affiliates of TPG... Read More

Thursday May 2, 2019 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, TPG Sixth Street Partners, ATHENA study, Rubraca

Clovis Oncology announces interim results for drug treating pancreatic cancer

Clovis Oncology announces interim results for drug treating pancreatic cancer

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced interim results from an investigator-initiated Phase 2 trial of Rubraca (rucaparib) in platinum-sensitive patients with advanced... Read More

Tuesday April 2, 2019 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca

Clovis Oncology: Rubraca now available in Germany for ovarian cancer therapy

Clovis Oncology: Rubraca now available in Germany for ovarian cancer therapy

BOULDER MUNICH -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced Rubraca (rucaparib) is now available by prescription in Germany as monotherapy for the maintenance treatment of adults with... Read More

Tuesday March 5, 2019 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology announces European Commission OK of Rubraca for ovarian cancer

Clovis Oncology announces European Commission OK of Rubraca for ovarian cancer

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the European Commission (EC) has approved the use of Rubraca(rucaparib) for treatment of ovarian cancer. Specifically, the... Read More

Monday January 28, 2019 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca, Rucaparib

Clovis Oncology announces positive hearing for Rubraca in Europe

Clovis Oncology announces positive hearing for Rubraca in Europe

BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153... Read More

Wednesday December 5, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy, Rucaparib

Clovis Oncology receives Breakthrough Therapy designation for Rubraca

Clovis Oncology receives Breakthrough Therapy designation for Rubraca

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced theU.S. Food and Drug Administration(FDA) has granted Breakthrough Therapy designation for Rubraca (rucaparib) as a monotherapy... Read More

Tuesday October 2, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy, FDA

Clovis Oncology receives European validation for Rubraca cancer drug

Clovis Oncology receives European validation for Rubraca cancer drug

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the European Medicines Agency (EMA) has validated the application for a Type II variation to the marketing authorization for Rubraca ... Read More

Thursday July 5, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology announces FDA approval of Rubraca for ovarian cancer treatment

Clovis Oncology announces FDA approval of Rubraca for ovarian cancer treatment

BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) announced the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets for the maintenance treatment of adult patients with... Read More

Monday April 9, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy